How would you manage patients with TNBC who achieve a pCR with neoadjuvant KEYNOTE-522 regimen, but develop isolated chest wall recurrence soon after completing neoadjuvant treatment?

Community
Company
News
Contact Us
Sign in

Topics: Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Yale • Triple negative • NCI-CCC Breast Tumor Board Question

Would you provide adjuvant therapy? Palliative therapy?

No evidence of distance metastases.

Related Questions

What estimated absolute benefit level of adjuvant chemotherapy for HR-pos HER2-negative breast cancer is worth recommending chemotherapy to patients?

What is your preferred adjuvant chemotherapy regimen for a patient with local recurrence of TNBC two years after completing neoadjuvant ddAC-T who declined prior adjuvant capecitabine?

In which scenarios do you stage breast cancer using CT and nuclear bone scans versus PET-CT?

Do you consider post-NAC isolated tumor cells in LNs to be residual disease in TNBC to justify capecitabine?

In which situations are you comfortable with alternative dosing of ovarian suppression (e.g Lupron q3m) for premenopausal patients during adjuvant breast cancer treatment?

Are there any scenarios you would use CDK 4/6i to treat HR-positive HER2-positive breast cancer in combination with anti-HER2 agents?

How do you manage adjuvant endocrine therapy for microinvasive HR-positive disease measuring >=1mm in extension?

Is there evidence for development of more severe autoimmune toxicities for young patients vs older patients on immune checkpoint inhibitors?

Would you recommend axillary lymph node dissection in a pre-menopausal woman with ER+ PR+ HER2- IDC, s/p lumpectomy and SLN with pT1c pN1 cM0 disease, where 2 sentinel nodes are positive for macrometastasis and 1 SN is positive for micrometastasis?

In which scenarios do you use vaginal estrogen in patients with history of HR positive breast cancer?